Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Dr Andrea Cherrington
+44 (0)1782 734875
a.cherrington@keele.ac.uk


Dr Laurna Bullock
+44 (0)1782 734988
l.bullock@keele.ac.uk


Ms Keele Clinical Trials Unit
+44 (0)1782 732916
ctu.operations@keele.ac.uk


Dr Zoe Paskins
+44 (0)1782 733975
z.paskins@keele.ac.uk


Ms Jo Smith
+44 (0)1782 733916
j.smith2@keele.ac.uk


More information about this study, what is involved and how to take part can be found on the study website.

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Being involved and informed: Improving appointments about your bone health
Back

Being involved and informed: Improving appointments about your bone health

Not Recruiting

Open to: All Genders

Age: Adult

Oxford Wolverhampton Portsmouth Stafford

Medical Conditions

Injuries and accidents, musculoskeletal

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The iFraP study team have developed a web-based visual tool called a ‘decision-support tool’ to support Fracture Liaison Service (FLS) healthcare professionals to know when to suggest treatments and aid conversations with patients about risk and to make decisions, for instance about starting osteoporosis medicines. The team have also developed training for healthcare professionals to help them use the tool and to ensure that the information they are giving is understandable, that they address patient concerns, and that they give clear, consistent information during the appointment. The decision-support tool and training package together are called the ‘iFraP intervention’. The iFraP study will look at whether the iFraP intervention makes decision-making about osteoporosis medicines easier, and whether it is cost-effective, acceptable and practical to deliver.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

31 Mar 2023 31 Mar 2024

Publications

2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/39145101/ (added 15/08/2024)

Participants will be asked to complete 3 questionnaires (one at baseline, one at 2 weeks and one at 3 months after their FLS appointment). They will also have the option to have their appointment recorded as well as a medical record review for information about their prescription initiation and continuation. A selection of participants will be invited to take part in an interview to find out what they thought of their FLS appointment. Participants will be involved in the study for a duration of 3 months follow-up. All participating FLS clinicians will be asked to consent to their consultations being recorded. FLS clinicians delivering the iFraP intervention and GPs consulting with patients after they receive the iFraP intervention will be invited to take part in an interview to discuss their experiences and views of the intervention.


Adults aged 50 years old and over who have been referred to an FLS consultation due to experiencing a fragility fracture, and who are able to attend a face-to-face or remote consultation. In addition, FLS clinicians involved in delivering the iFraP intervention and GPs consulting with iFraP intervention participants will be invited to an interview as part of the process evaluation.

You can take part if:



You may not be able to take part if:


1. Patients who are unable to give full informed consent or unable to comply with study procedures 2. Patients with a friend or relative in the study (identified through self-report)


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Oxford University Hospitals NHS Foundation Trust
    John Radcliffe Hospital Headley Way Headington
    Oxford
    OX3 9DU
  • The Royal Wolverhampton NHS Trust
    New Cross Hospital Wolverhampton Road Heath Town
    Wolverhampton
    WV10 0QP
  • Portsmouth Hospitals University National Health Service Trust
    Queen Alexandra Hospital Southwick Hill Road Cosham
    Portsmouth
    PO6 3LY
  • Midlands Partnership NHS Foundation Trust
    Trust Headquarters St Georges Hospital Corporation Street
    Stafford
    ST16 3SR

There are no anticipated direct benefits to the research participants of taking part in this study. However, the information gained from this study will improve information and advice for future information for FLS patients about their bone health and when considering bone health treatments. The study involves relatively low risks and levels of burden which are considered to be no higher than that of usual medical care.

Dr Zoe Paskins
+44 (0)1782 733975
z.paskins@keele.ac.uk


Ms Jo Smith
+44 (0)1782 733916
j.smith2@keele.ac.uk


Dr Andrea Cherrington
+44 (0)1782 734875
a.cherrington@keele.ac.uk


Ms Keele Clinical Trials Unit
+44 (0)1782 732916
ctu.operations@keele.ac.uk


Dr Laurna Bullock
+44 (0)1782 734988
l.bullock@keele.ac.uk



More information about this study, what is involved and how to take part can be found on the study website.


The study is sponsored by Keele University and funded by National Institute for Health and Care Research.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN10606407

Or CPMS 53843

Last updated 25 September 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top